CULLINAN THERAPEUTICS, INC. (CGEM) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $3.73M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $1.53M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $3.73M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $3.73M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $1.53M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $1.53M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 42.03M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 3.73M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | 1.53M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $1.53M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $2.07M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.73M | (m) | $1.53M | (m) | $42.03M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $2.51M | (m) | $1.35M | (m) | $36.81M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $841.00K | (m) | $996.00K | (m) | $39.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.72M | (m) | $1.51M | (m) | $32.76M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.46M | (m) | $2.23M | (m) | $28.18M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $3.40M | (m) | $2.79M | (m) | $27.84M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.68M | (m) | $1.44M | (m) | $31.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $2.12M | (m) | $1.71M | (m) | $25.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.55M | (m) | $2.22M | (m) | $25.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $3.71M | (m) | $1.52M | (m) | $23.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $2.49M | (m) | $914.00K | (m) | $30.29M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $951.00K | (m) | $1.58M | (m) | $25.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.49M | (m) | $1.03M | (m) | $22.41M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.03M | (m) | $5.11M | (m) | $29.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $2.66M | (m) | $1.96M | (m) | $26.09M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.52M | (m) | (m) | (m) | $31.11M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.10M | (m) | (m) | (m) | $62.63M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $6.31M | (m) | (m) | (m) | $17.99M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.17M | (m) | (m) | (m) | $11.81M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.02M | (m) | (m) | (m) | $7.93M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.51M | (m) | (m) | (m) | $5.81M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.88M | (m) | (m) | (m) | $9.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $9.68M | (m) | (m) | (m) | $14.39M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |